奧賽康(002755.SZ):甲氨蝶呤注射液獲得藥品註冊證書
格隆匯6月22日丨奧賽康(002755.SZ)發佈公告,公司的全資子公司江蘇奧賽康藥業有限公司於近日收到國家藥品監督管理局覈準簽發的甲氨蝶呤注射液《藥品註冊證書》。
根據披露,甲氨蝶呤是一種二氫葉酸還原酶抑制劑類藥物,可幹擾DNA合成、修復和細胞複製,具有廣譜抗腫瘤活性,可單獨使用治療乳腺癌、妊娠性絨毛膜癌等,或與其它化療藥物聯合使用治療成骨肉瘤、急性白血病等,大劑量單獨應用或與其它化療藥物聯合應用治療成骨肉瘤、急性白血病、支氣管肺癌或頭頸部表皮癌,以及用於銀屑病化療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.